Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries by Ramaswami, U. (Uma) et al.
Contents lists available at ScienceDirect
Atherosclerosis
journal homepage: www.elsevier.com/locate/atherosclerosis
Comparison of the characteristics at diagnosis and treatment of children
with heterozygous familial hypercholesterolaemia (FH) from eight European
countries
Uma Ramaswamia,1, Marta Futemab,1, Martin P. Bogsrudc,d, Kirsten B. Holvenc,e,
Jeanine Roeters van Lennepf, Albert Wiegmang, Olivier S. Descampsh, Michal Vrabliki,
Tomas Freibergerj,k, Hans Dieplingerl, Susanne Greber-Platzerm, Gabriele Hanauer-Madern,
Mafalda Bourbono, Euridiki Drogarip, Steve E. Humphriesq,∗
a Lysosomal Disorders Unit, Royal Free Hospital, London, UK
b Centre for Heart Muscle Disease, Institute for Cardiovascular Science, University College London, London, UK
cNational Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
dUnit for Cardiac and Cardiovascular Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
e Department of Nutrition, University of Oslo, Oslo, Norway
fDepartment of Cardiology and Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
g Department of Pediatrics and Academic Medical Center, Amsterdam, the Netherlands
h Centres Hospitaliers Jolimont, Lipid Clinic, Haine-Saint-Paul, Belgium
i Third Department of Internal Medicine, General University Hospital and First Faculty of Medicine, Charles University, U Nemocnice 1, 128 08, Prague 2, Czech Republic
j Centre for Cardiovascular Surgery and Transplantation, Pekarska 53, 656 91, Brno, Czech Republic
kMedical Faculty, Masaryk University, Brno, Czech Republic
l Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Schöpfstraße 41, 6020, Innsbruck, Austria
mDivision of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Austria
n FH Registry of the Austrian Atherosclerosis Society, Vienna, Austria
o Cardiovascular Research Group, Research and Development Unit, Department of Health Promotion and Chronic Diseases, National Institute of Health Doutor Ricardo
Jorge, Lisbon, Portugal and University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Lisboa, Portugal
p First Department of Pediatrics, National and Kapodistrian University of Athens and Department of Inborn Errors of Metabolism and Inherited Dyslipidemias, “MITERA”
Children's Hospital, Athens, Greece
q Centre for Cardiovascular Genetics, Institute for Cardiovascular Science, University College London, London, UK
H I G H L I G H T S
• The age of HeFH diagnosis varies significantly between 8 European countries.• The proportion of HeFH children being treated varies across 8 European countries.• A quarter of FH children on statins have LDL-C above the target (> 3.5 mmol/L).• Many FH children are not getting the full benefit of early diagnosis and treatment.
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A B S T R A C T
Background and aims: For children with heterozygous familial hypercholesterolaemia (HeFH), European
guidelines recommend consideration of statin therapy by age 8–10 years for those with a low density lipoprotein
cholesterol (LDL-C)>3.5 mmol/l, and dietary and lifestyle advice. Here we compare the characteristics and
lipid levels in HeFH children from Norway, UK, Netherlands, Belgium, Czech Republic, Austria, Portugal and
Greece.
Methods: Fully-anonymized data were analysed at the London centre. Differences in registration and on treat-
ment characteristics were compared by standard statistical tests.
Results: Data was obtained from 3064 children. The median age at diagnosis differed significantly between
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countries (range 3–11 years) reflecting differences in diagnostic strategies. Mean (SD) LDL-C at diagnosis was
5.70 (± 1.4) mmol/l, with 88% having LDL-C> 4.0 mmol/l. The proportion of children older than 10 years at
follow-up who were receiving statins varied significantly (99% in Greece, 56% in UK), as did the proportion
taking Ezetimibe (0% in UK, 78% in Greece). Overall, treatment reduced LDL-C by between 28 and 57%,
however, in those> 10 years, 23% of on-treatment children still had LDL-C>3.5 mmol/l and 66% of those not
on a statin had LDL-C> 3.5 mmol/l.
Conclusions: The age of HeFH diagnosis in children varies significantly across 8 countries, as does the proportion
of those> 10 years being treated with statin and/or ezetimibe. Approximately a quarter of the treated children
and almost three quarters of the untreated children older than 10 years still have LDL-C concentrations over
3.5 mmol/l. These data suggest that many children with FH are not receiving the full potential benefit of early
identification and appropriate lipid-lowering treatment according to recommendations.
1. Introduction
Familial hypercholesterolaemia (FH) is an autosomal dominant in-
herited disorder characterised by elevated low-density lipoprotein
cholesterol (LDL-C) levels from birth [1]. This causes a greatly elevated
risk of premature coronary heart disease (CHD) in middle age [2],
which can be significantly reduced by statin therapy [1,2]. Recent
studies have reported that the prevalence of heterozygous FH (HeFH) is
around 1 in 250 in a number of different countries [3–5], though it is
currently unknown if this prevalence is the same in all countries in
Europe. FH is most often due to carriage of a mutation in the LDLR
gene, which encodes the low-density lipoprotein receptor (LDL-R), but
mutations in apolipoprotein B (APOB), and proprotein convertase
subtilisin/kexin type 9 (PCSK9), can produce a phenotype identical to
FH due to mutation in LDLR [6]. In patients where no causative mu-
tation can be found a polygenic cause of their hyperlipidaemia is most
likely [7,8]. Once identified, subjects with FH can be offered healthy
life style advice to decrease their elevated cardiovascular risk (e.g.
avoiding or stopping smoking, healthy eating, exercise) and lipid-low-
ering therapies.
In the last 10 years, many National and European guidelines have
been published for the identification and management of children with
FH [1,2,9–15]. The UK Simon Broome FH diagnostic thresholds for
children under the age of 16 years include: total cholesterol> 6.7
mmol/l and LDL-C>4.0 mmol/l [2]. In the UK the 2008 NICE
Guideline (CG71) recommends statin therapy should be considered by
the age of 10 years [15], while European guidelines on the management
of FH in childhood proposed that statin use should be considered from
the age of 8 years, and that LDL-C be lowered below 3.5 mmol/l if
possible [11]. Both recommend use of Ezetimibe as an adjunct to statin
therapy in those over the age of 10 years who are statin-intolerant or
who have not achieved the LDL-C target.
The initiation of lipid-lowering therapy in children with FH is de-
termined by factors such as the child's current LDL-C levels, the age of
onset of CHD in relatives, and the presence of other CHD risk factors
[e.g. obesity or level of Lp(a)] [16]. Although follow-up of children
with FH who were started on a statin by the age of 10 years supports the
potential CHD benefit [11,17], the age at which statin use should be
started, or its intensity to best prevent the onset of adult premature
CHD has not been rigorously established, since there are no long-term
randomized controlled outcome trials for ethical and practical reasons.
There is, however, considerable short term randomized and observa-
tional data on the utility of statin therapy in children with HeFH,
showing a good safety profile, without liver toxicity side effects, no
influence on growth trajectory and excellent efficacy in terms of LDL-C
reduction over periods of 2–3 years [18–21].
While the European guidelines and country specific guidelines are
relatively similar in their recommendations for the total and LDL-C
thresholds for a clinical diagnosis of FH and treatment strategies,
adoption of these recommendations are likely to be influenced by local
factors such as clinician and parental preferences and the different
health care and reimbursement systems for lipid-lowering therapy. The
UK National Paediatric FH Register was established in 2012 to collect
baseline and long term follow-up data on children with a clinical di-
agnosis of HeFH in UK [22,23]. In 2017 we obtained funding from the
International Atherosclerosis Society (IAS) to collect similar data from
seven other European countries, to establish an International Paediatric
FH Register and to compare across Europe the characteristics at diag-
nosis, including the proportion with an identified mutation and the
proportion of children with LDL-C < 4.0 mmol/l, and the age of in-
itiation and lipid-lowering effect of statin treatment in the different
countries. Although information on children in the UK [22], Portugal
[24], The Netherlands [25] and Norway [26] cohorts has been pub-
lished previously, the novelty of this present study is the analysis of the
between-country similarities and differences in diagnostic and treat-
ment strategies currently being used.
2. Patients and methods
2.1. Register criteria
Based on the UK register [22,23] a “minimum data set” and data
dictionary of 86 key variables was developed (available on request from
authors). As no funding was available for study-specific (or registry
specific) data collection, only centres already having available such
data from children and young people (under the age of 18 years) were
asked to participate. Any child with a local diagnosis of heterozygous
FH (either clinical or genetically verified) were included. Homozygous
FH was excluded. For Greece, the referring clinician requested that only
those with an identified mutation should be included. This study is
therefore a retrospective dataset designed to allow comparison of the
different ways in which children with FH are being identified and
treated. See Supplementary Table 1 for presentation of the key selection
criteria and time frame variables.
2.2. Country-specific patient identification
Norway: Data were collected retrospectively to a treatment quality-
register, from medical records of children below 18 years with a diag-
nosis of heterozygous FH, visiting the Lipid Clinic, Oslo University
hospital during 2014–2016. Only children with a confirmed pathogenic
mutation in the LDLR gene, the p.R3500Q mutation in APOB, or PCSK9,
or children with LDL-C concentrations> 4.9 mmol/l and a first or
second degree relative with such a mutation, were included. All genetic
tests were performed by the Unit for Cardiac and Cardiovascular
Genetics at Oslo University Hospital. Data on diagnosis, lipid levels,
other relevant blood chemistry, lipid-lowering therapy, diet and
smoking habits were collected. Details has been described before [26].
The treatment quality register was approved by the Regional Com-
mittee for Medical and Health Research Ethics and the Data Protection
Official at Oslo University Hospital. Informed consent is not required in
Norway for this type of data collection used for quality of treatment
purposes. Sending fully-anonymized data to UK was approved by the
hospital and did not require new Ethics committee approval.
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UK: All lipid clinics in the UK and paediatricians with an interest in
lipid disorders were contacted electronically and details of the register
provided. An electronic web based data capture tool was developed to
collect information. The register captures routine clinical data, demo-
graphy, family history, treatments and lifestyle details, and clinicians
are sent an electronic reminder to fill in annual follow up data. Full
details of the establishment and governance of the Register have been
published [22]. Data on children registered between July 2012 to No-
vember 2014 were included. Children were diagnosed as having FH
based on the UK Simon Broome criteria [2], with the majority having
been identified by family studies from an index case with a clinical
diagnosis of FH.
The Netherlands: Data was collected from all consecutive children
with FH who visited the outpatient lipid clinics of the Erasmus MC or
Sophia Children Hospital The Netherlands for the first time under 18
years old, between April 1993 and February 2018 and was entered in a
database. The diagnosis of FH was based either on identification of a FH
pathogenic variant in LDLR//APOB/PCSK9 or Dutch Lipid Clinic
Network criteria with definite FH score ≥8 [25,27]. Children with
homozygous FH were excluded. Most children were referred because
they had a parent diagnosed with FH. The Medical Ethical Review
Committee of the Erasmus MC, The Netherlands, considered the pro-
tocol non-Medical Research Involving Human Subjects Act (WMO)
therefore review of the protocol was waved (MEC-2017-1197).
Belgium: Data were obtained retrospectively from a review of the
medical record of one lipid clinic in one department of internal medi-
cine for the vast majority, as well as from a paediatric consultation for a
dozen patients over the period 2014–2018. This situation reflects the
general situations in Belgium where testing cholesterol levels in chil-
dren is still rare in paediatric consultation. The children seen in an
internal medicine consultation are most often those of parents who are
followed in the adult consultations for their FH. The diagnosis of FH in
their parent was based either on identification of a FH pathogenic
variant in LDLR//APOB/PCSK9 or Dutch Lipid Clinic Network criteria
with definite FH score ≥8 (see above). A small proportion of children
were sent directly by their doctor, who have measured lipid con-
centrations following the discovery of a suspicion of FH or following the
start of treatment for acne. FH in children was confirmed using either
the LDL-C cut-off previously published [11] or by genetic testing. Col-
lecting the data, encoding in a anonymized file and sending the data to
UK was approved by the local hospital ethical committee. Informed
consent is not required in Belgium for this type of data collection.
Czech Republic: Data were obtained from the Czech MedPed reg-
istry, with collection of children data over the period 1998–2018. There
are two different ways that children with FH get registered within a
national MedPed database. Approximately 50% have been identified
through cascade screening. These are children of FH adult patients
being invited to visit paediatric FH centre affiliated with a regional
adult FH centre. Plasma lipid levels are examined and clinical diagnosis
is established. Genetic testing is offered to be done in a child, if a dis-
ease-causing mutation is known in the family. The remainder have been
identified from a nationally adopted selective FH screening programme
or from the other health care-related blood testing. The Paediatric care
network is well established in the Czech Republic and 98% of the
children receive bi-annual preventive check-ups. Since 1998 paedia-
tricians have been instructed by local guidelines to perform selective
dyslipidaemia screening in families affected with a) known familial
dyslipidaemia running in the pedigree (e.g. diagnosis established in
first/second degree relatives) or b) premature atherothrombotic vas-
cular complications in first/second degree relatives. The paediatrician
should ask about the presence of the two for the first time during the
preventive check-up at age of 5 and repeat the investigation once again
at the check-up at age of 13. Once the response to any of the two
questions from the parent/guardian is positive, the child is referred for
blood sampling and plasma lipid levels are assessed. Where they exceed
age and gender specific values of 95th percentile of total and/or LDL-
cholesterol distribution, they are referred to the regional paediatric FH
centre for specialised counselling. Here plasma lipid levels are mea-
sured again, a thorough medical examination focusing on subclinical
atherosclerosis is performed and secondary causes of dyslipidaemia
excluded. The suspected FH child's data are then entered in the national
database and FH criteria fulfilment is checked by one of two members
of the MedPed CZ project who then approve (or disprove) submitting
the patients' material for genetic analysis. Genetic testing is offered to
the family together with examination of all available relatives of the
proband in the case a disease-causing mutation being detected. Patients
with FH diagnosis confirmed based on clinical and/or molecular cri-
teria continue being followed at the MedPed centre with a frequency
twice a year at minimum.
Austria: Data were obtained from an FH registry project initiated by
the Austrian Atherosclerosis Society in 2015. This project started as a
pilot project at the three Medical Universities in Vienna, Graz and
Innsbruck and now also involves other medical centres/hospitals in
Austria. By the summer of 2018 (when the data from FH-affected
children were evaluated), 350 FH patients had been recruited into the
registry. FH-affected children (< 19 years old) were (clinically) diag-
nosed according to the Simon-Broome criteria as described [28]. The
software platform Askimed developed at the Institute of Genetic Epi-
demiology of the Medical University of Innsbruck was used for data
entry, management and monitoring (www.askimed.com).
Portugal: Data from 294 FH children was collected anonymized
from the Portuguese FH Study, a nation-wide study started in 1999 at
the National Institute of Health. All children with ages up 21 years old
in 2018 referred to this study as index fulfilled FH clinical criteria
(Simon Broome) were included and also children that were relatives of
adult patients with a causative mutation. All clinicians were contacted
to update the information in the last visit on lipid profile, treatment,
lifestyle as smoking habits and age of menarche. Updated information
was only available for 125/294 individuals.
The Greek Paediatric FH Register: In 1993, the Paediatric FH
Registry was started at the Unit for Inherited Metabolic Disorders (IEM)
(director Professor Euridiki Drogari) at the Choremio Research
Institute, of the 1st Department of Paediatrics, National and
Kapodistrian University of Athens, at the “Agia Sofia” Children's
Hospital in Athens. The collection period is thus 1993–2018.
Paediatricians throughout Greece were requested to measure choles-
terol levels in all children around the age of 3 years, and if levels were
above the 97th centile for age and sex, the children were referred to the
Athens Metabolic Clinic. During the first two visits cascade screening
for three continuous generations was performed in all members of the
families. Children and adults who fulfilled the Simon Broome clinical
and biochemical criteria for FH were offered molecular analysis from
University lab dedicated to this purpose. The patients were screened for
mutations in three genes (LDLR/APOB/PCSK9), and to date, no APOB
and PCSK9 mutations have been found in the Greek population [29],
and from a database of several thousand cases all 1000 children se-
lected had an identified LDLR mutation. When children reached the age
of 8 years they start treatment with statins or ezetimibe alone or in
combination. Close follow up between three and six months for the lipid
profile together with the growth and development during treatment
was performed for each child until the age of 17–18 years. The FH
adults were referred to Lipid Adult Specialists.
Approvals: Approvals of data collection and sharing was obtained
in each country according to national regulations. Although data was
already fully-anonymized, data was sent as an excel sheet in a pass-
word-protected file, with the password sent separately. Data was stored
in the UCL Data Safe Haven, which is fully GDPR-compliant.
Statistical methods: Results for continuous variables are presented
as mean (± standard deviation) and median (with interquartile range),
and differences by sex and statin use are tested using Mann-Whitney U
tests. Differences in the fall in LDL-C by statin use are adjusted for age
using analysis of covariance. Changes in lipid levels are the difference
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between the baseline registration and follow-up of the patient.
Categorical variables are presented as percentages and numbers, and
tested using chi-squared tests or Fisher's exact test. Changes in LDL-C by
statin use were analysed using analysis of covariance with adjustment
for age and length of follow-up. In order to address potential issues of
the large sample of children from Greece inflating statistical differ-
ences, p values for contrasts are presented with and without the in-
clusion of the Greek children. For conversion to mg/dl, mmol/l con-
centrations of total and LDL-C should be multiplied by 38.67. In a
proportion of Portuguese (6%) children the baseline untreated LDL-C
was not available therefore the untreated concentrations were imputed
from latest recorded LDL-C using the method as described [30], which
adjusts for the type and dose of the lipid-lowering treatment.
3. Results
3.1. Baseline characteristics
In all countries, the children were identified mainly by cascade
screening, except in Portugal and Czech Republic where>80% and
50% respectively of the children were referred as index cases identified
from routine health screening tests. Baseline data shown in Table 1
includes 3064 HeFH children (48% boys), with a baseline mean (SD)
LDL-cholesterol (LDL-C) of 5.70(1.44) mmol/L. Untreated LDL-C con-
centrations were ranging from 4.87 mmol/l in Austria to 6.21 mmol/l
in Greece (Supplementary Figure 1). The median (interquartile range)
age at diagnosis differed significantly, ranging from 3 [1] years in
Greece to 11 [6] years in the Netherlands and Belgium. The prevalence
of a family history of early CHD in any relative differed significantly
(p < 0.0001) being higher in countries in the North of Europe than in
the South. After excluding the Greek cohort, where all children had an
identified FH mutation, the average proportion of the children carrying
an identified FH-causing mutation was 79%, ranging from 61% in
Portugal to over 90% in Norway, the Netherlands and Belgium. The
majority of mutation carriers had a pathogenic variant in the LDLR
gene. On average 10% of the genetic causes were due to a mutation in
APOB, though the frequency of the APOB defect varied between the
countries, being the most common in children from Czech Republic,
accounting for 39% of all FH-causing mutations, and not present in the
Greek children (Supplementary Table 3).
Overall, more than 90% of the children had an untreated LDL-C
of> 4.0 mmol/l, with the lowest proportion being 71.9% in Austria
and the highest 99.4% in Greece. The overall characteristics of the
children with LDL-C below 4.0 mmol/l are presented in Supplementary
Table 2. Compared to those with baseline LDL-C>4.0 mmol/l the<
4.0 mmol/l group had a marginally higher proportion with a reported
family history of CHD (18.9% vs. 14.5%, p = 0.06) and as expected
lower mean total- and LDL-C and lower triglycerides, with fewer of
these children receiving a statin (23% vs. 59%, p < 2x10−16). The
proportion with a FH-causing mutation was not different between the
two groups (87.9% vs. 89.3%, p = NS).
3.2. Lipid-lowering therapy
Follow-up data was available for over 90% of children, although
with less data from the Czech and Portuguese cohorts with 29% and
48%, respectively. The median (interquartile range) follow-up period
was 6(7) years. Over this period, a considerable proportion of the
children were initiated on lipid-lowering therapy. As shown in
Supplementary Table 4, the commonly used statins were Atorvastatin
(47%; n = 794), Simvastatin (32%, n = 537), Rosuvastatin (13%,
n = 233), and Pravastatin (8%, n = 131). Of all those patients re-
ceiving any form of a treatment (n = 1789) a small proportion were on
resins (2%, n = 36). There was a significant difference in the propor-
tion of children taking Ezetimibe between countries, ranging from 0%
in the UK to 78% in Greece (Supplementary Table 4). Overall, 46% of
those on treatment were receiving Ezetimibe, mostly (99%) as a com-
bination treatment with a statin. No patients were on fibrates and the
use of plant stanols was limited (0.1%, n = 1).
The proportion of children taking lipid lowering therapy by follow-
up age is shown in Fig. 1 (and Supplementary Table 5) and the baseline
characteristics of those later taking and not taking a statin are shown in
Supplementary Table 6. Overall, there was a significantly higher pro-
portion of those where a mutation had been identified in the treated
compared to the not treated group (93% vs. 76%, p < 2.2 x 10−16) and
a slightly higher proportion of boys than girls on treatment (50% vs.
Fig. 1. Proportions of children receiving statins by age at follow up per country.
Children with follow-up data were grouped into age category (1. younger than 8 years, 2. from 8 to 10 years, 3. 10–15 years, and 4. over 15 years of age).
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46% p = 0.02). As shown in Supplementary Table 8, possible factors
explaining this are that a higher proportion of boys than girls had a
detected mutation (87% vs. 84% p= 0.05), and a family history of CHD
(10% vs. 8% p= 0.01), but overall the boys had a lower mean age (7yrs
vs. 8yrs (p = 0.0002) and a lower mean baseline total cholesterol
(7.48 mmol/l vs. 7.62 mmol/l, p = 0.01). At diagnosis, the mean
concentrations of triglycerides were slightly lower (p= 0.008) and HDL
were slightly higher (0.02) in those who were subsequently on statin
treatment. Mean diagnostic levels of total and LDL-C were significantly
higher in the subsequently treated group (for LDL-C, mean (SD) 6.01
(± 1.35) mmol/l vs. 5.26 (± 1.43) mmol/l, p < 2.2 x 10−16). The
number of children under the age of 8 with available follow-up data
was small, representing only 11% of all cohorts (n = 256), (7% when
the Greek cohort was excluded). Nevertheless, as expected, in all
countries, the proportion of children on a statin under the age of 8 years
was low, being overall 5% and ranging from 0% in Czech Republic and
Greece to 40% in Belgium. The proportion taking a statin increased
with increasing age, and overall was 74% in 8–10 year olds, 79% in
11–15 year olds and 82% in those over the age of 15 years. As shown in
Fig. 2, significant between-country differences were apparent, with the
proportion of children aged over 10 years not taking statins ranging
from 1% in Greece to 44% in the UK (Chi2 = 270, df = 7, p < 2.2 x
10−16).
As shown in Table 1 and Fig. 3, in those on statin treatment, LDL-C
levels were significantly reduced compared to the values at the time of
FH diagnosis by an average of 46% (2.86 (1.61)mmol/l), with children
in Greece achieving a 57.4% reduction. There were minor differences
between the rest of the countries in the extent of LDL-C lowering seen
(ranging from 28.1% in Austria to 43.9% in Czech Republic). At follow-
up, in children older than 10 years, LDL-C was significantly lower in
those receiving the treatment (3.20 (1.1) vs. 4.32 (1.3), p < 2.2 x
10−16), as shown in Supplementary Table 9. Treatment reduced LDL-C
levels below the recommended 3.5 mmol/L cut-off in 77% of over 10
year olds (in 55% if the Greek cohort was excluded). However, of those
over 10 years of age, who did not receive treatment, 66% had LDL-
C> 3.5 mmol/L at the latest visit (Supplementary Table 9). Of the 352
children over 10 years old not on a statin, 66% had levels over the
suggested target of 3.5 mmol/l. Overall, of the children over the age of
10 years on statins, 42% were also taking ezetimibe (Supplementary
Table 4). As expected the mean (± SD) baseline LDL-C of those taking
ezetimibe was higher than in those not on ezetimibe (6.56 (± 1.29)
mmol/l vs. 5.57 (± 1.32) mmol/l, p < 2.2 x 10−16) and the treated
LDL-C was lower (2.73 (± 0.66) vs. 3.56 (± 1.26) mmol/l, p < 2.2 x
10−16). The overall mean (SD) reduction in LDL-C in those taking
ezetimibe was higher (56.9% vs. 35.4%, p < 2.2 x 10−16) and the
proportion achieving a treated LDL-C below 3.5 mmol/l was higher
(92% vs. 53%, p < 2.2 x 10−16).
3.3. Treatment in those> 10 years
Finally, we examined in each country data the characteristics of the
children over the age of 10 years, which is the age by which the UK
NICE FH guideline [15] and the European Consensus guidelines [11]
recommend that initiation of statin therapy should be considered.
Austria was excluded from the analysis as no follow-up data was
available. As shown in Fig. 2 and Supplementary Table 9 the proportion
of the children receiving statin therapy varied significantly, ranging
from 56% in the UK to 99% in Greece. In those not being treated with a
statin at follow-up, the mean TC and LDL-C concentrations recorded at
time of diagnosis and referral (baseline) were significantly lower than
those on statin treatment on follow-up, and for example, overall, in the
children over 10 years not on statins, LDL-C concentrations at diagnosis
were 20% lower than those who went on to receive treatment (4.85
(± 1.3) vs. 5.99 (± 1.4) mmol/l, p < 2.2 x 10−16). In addition, the
proportion of those who were on statins who had an identified FH-
causing mutation was significantly higher than in those who were not
on statins (92% vs. 70%, p < 2.2 x 10−16).
4. Discussion
This analysis of one of the biggest sets of data of children with FH
examined to date, with 2623 with a known mutation, has made three
major findings. The first is that across the eight European countries the
mean age at diagnosis is very different, ranging from 3 years in Greece
to 11 years in the Netherlands and Belgium. This is not surprising given
the very different care-pathways, policies and diagnostic strategies used
Fig. 2. Statin treatment in children older than 10 years of age (at follow-up) per country.
Stacked bars represent number of treated and untreated children in each cohort. The percentage on top of each bar shows the proportion of children on statins.
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in the different countries and to a large extent reflects the maturity of
the FH child diagnostic work across Europe, with the paediatrician in
Greece having started clinical practice more than 20 years ago, routi-
nely testing cholesterol concentrations in all children before the age of
3. In the other countries where diagnosis is performed mainly through
family cascade screening (after known diagnosis in parent) the median
age at diagnosis is between 8 and 11 years, which is in line with pae-
diatric FH guidelines that recommend the testing and identification of
children at risk of FH by the age of 8–10 years [9–14]. The lipid profile
at diagnosis is relatively uniform across countries, with mean LDL-C
5.70 (± 1.44) mmol/l, although with Greece having the highest and
Austria the lowest values, due most probably to patient selection cri-
teria. Of the children, more than 88.5% had an untreated LDL-C of>
4.0 mmol/l, which is the diagnostic cut-off recommended by the UK
Simon Broome Register. In all countries, triglyceride values were low.
Data on the family history of CHD was not collected in all countries, but
showed a modest north-south gradient, as has been reported for the
general population. The proportion of children with an identified mu-
tation varied significantly across countries, but this mainly reflects the
availability of DNA testing services. The cohort from Greece was se-
lected from a large data base and only those with an identified mutation
were included. Previous work has identified a mutation in 53% of the
children on the Greek database [31]. To date no patient in Greece has
been identified carrying an APOB or PCSK9 mutation and 6 LDLR
mutations together explain ~80% of patients with a detectable muta-
tion [29]. As expected from previous country comparisons on adult
patients with FH, the proportion of children with LDLR, APOB or PCSK9
mutations also varied significantly between the countries, and analysis
of the relationship between the identified mutation and patient char-
acteristics will be presented elsewhere.
The second major finding relates to the proportion of children
taking a statin, the different ages where statin therapy has been in-
itiated, and the different statins being used. In line with published re-
commendations and licensing requirements, in all countries the pro-
portion of children on a statin under the age of 8 years was low, but
with wide country differences ranging from 0% in Czech Republic and
Greece to 40% in Belgium. These proportions need, however, be taken
with caution as the number of children under 8 years old with follow-up
data was small, accounting for only 7% of the cohort (n = 94), when
excluding Greece. The proportion taking a statin increased with in-
creasing age, and by the age of 15 years 79% of children were taking a
statin, but again with large between-country differences, with the
proportion not taking statins at the age of 15 ranging from 1% in Greece
to 49% in the UK. Overall, a slightly higher proportion of boys than
girls were on a statin at follow-up, and although this difference may at
least partly be explained by the higher proportion of boys than girls
with a detected mutation and a higher prevalence of a family history of
CHD, baseline levels of total cholesterol were lower in boys than girls, it
does suggest that girls may be being undertreated. While Atorvastatin is
the most common statin and is used in all countries, simvastatin is also
commonly used in all countries except Norway and rarely in Belgium,
while pravastatin is only used commonly in UK, The Netherlands,
Belgium and Portugal.
As expected, statin treatment lowered mean LDL-C levels sub-
stantially, with children in Greece achieving a 57.4% reduction and
minor differences between the rest of the countries, ranging from 28%
in Austria to 44% in the Czech Republic. In part, the large LDL-C re-
duction in children in Greece is a result of them having the highest LDL-
C at diagnosis, but of note, 78% of the Greek children were also taking
ezetimibe. This may also in part be because of healthy lifestyle and
dietary advice being given from an early age. Differences in LDL-C
lowering are explained mostly because of the different mix of statin
used in the different countries. As the only licensed hydrophilic statin
for children under 10 years of age, Pravastatin was being taken by
between one quarter and one third of children in UK, Netherlands and
Portugal, but by few or no children in the other countries. A high po-
tency statin (atorvastatin or rosuvastatin) was being taken by essen-
tially all children in Norway and Belgium, but by 41% of children in
Portugal, and between 51% and 73% in the other countries.
Use of ezetimibe as an adjunct to statin therapy is recommended for
adults with FH who are statin intolerant or who fail to reach target on
statin alone [1,15] and for children over the age of 10 years [11,15],
Fig. 3. Baseline and treated LDL-C in children who went on receiving statins.
The percentage on top of latest LDL-C bars represent the reduction in LDL-C by treatment in each cohort.
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where efficacy and safety have been documented [32]. Apart from in
Greece, ezetimibe was used in all countries at a low and varying fre-
quency as an adjunct to statin therapy. This low use might have been
caused by the relatively high price at the time of analysis and because of
relatively limited evidence of its use in children. However, the data here
shows that, as expected, ezetimibe use lowers LDL-C significantly and
that more than 90% of children taking a statin plus ezetimibe achieve
LDL-C below the EAS guideline recommendation of 3.5 mmol/l [11],
compared to only 53% of those on statin only. Overall, 23% of the
treated children older than 10 years still had LDL-C values above the
EAS recommendation of 3.5 mmol/l, and apart from the Greek children
(where 99% achieved this target), between 41 and 56% of treated
children had LDL-C above this level. Poor adherence (for example
during adolescence) or scepticism among doctors or parents to increase
statin dose or prescribe additional agents may be a contributing factor,
but we did not collect data on this.
The third major finding is that a significant proportion of the chil-
dren above the age of 10 years who were not on lipid-lowering therapy
had LDL-C concentrations above the 3.5 mmol/l EAS recommendation
for statin initiation). In the dataset as a whole, 352 (20%) of the 1776
children who were over the age of 10 years were not on a statin. Mean
latest LDL-C for these untreated children was 4.32 (1.33) mmol/l and
233 (66%) had LDL-C over 3.5 mmol/l. There may be a number of
reasons why a particular child is not taking lipid-lowering therapy, but
we were unable to collect any standardised information about this. In
the UK register, reasons for not being on lipid-lowering medication
included weak or absent evidence of a family history of early CHD,
which would support the decision to delay initiation, and parental
concerns about safety, (particularly if the affected parent had experi-
enced statin-related side effects). Some UK clinicians were also waiting
to receive DNA testing results before statin initiation [22]. It is likely
that such issues are also seen in all European countries.
A small proportion (< 10%) of the children had an untreated LDL-C
below the Simon Broome diagnostic threshold of 4.0 mmol/l. Perhaps
unsurprisingly, fewer of these children were receiving a statin (23% vs
59%), since for the majority their LDL-C is below the threshold for in-
itiating lipid-lowering therapy. Overall, 88% carried an FH-causing
mutation, suggesting that the majority of these children are on their
country FH register because of being identified through cascade testing
from a mutation positive relative. Few data exits on the future lipid-
trajectory in children with a pathogenic FH mutation, but one report
[33] showed that 11 of 25 children with an FH mutation and LDL-C
below 3.5 mmol/L developed hypercholesterolemia during 3.8 years of
follow up. It is possible that children with low LDL-C in our study may
have inherited a “milder” mutation, and a detailed analysis of the
genotype-phenotype relationships is in preparation.
4.1. Strengths and limitations
One of the major strengths of this large dataset is that it allows a
snapshot of the way children with FH are currently being treated across
different countries in Europe. To do this we created a “minimum data
set” and data dictionary of key variables (available on request from
authors) which we believe should be helpful in any future cross-country
comparisons. The main limitation is that not all countries had routinely
been collecting all the data analysed here, and for example collection of
the family history of CHD was missing from several countries. For
young children, whose parent are likely to be aged only 30–40 years
old, a family history of premature CHD in their first degree relatives is
very unlikely, and so the definition was expanded to include premature
CHD in second degree relatives, for example in grandparents. While this
data may be more relevant in making a clinical decision about statin
initiation, the accuracy of such data is often hard to verify. However
age of onset of premature CHD in relatives is a key factor in the clinical
decision as to the age to initiate statin therapy [9–15], and therefore
standardisation of this information would be very helpful. Similarly, we
requested plasma levels of Lp(a), a well-known CHD risk marker, but
this had not been routinely measured across the countries. We did not
collect information on dietary differences across countries, as these
would have been difficult to standardise, but these are likely to have
contributed to some extent to the differences in characteristics seen
here. A further limitation is that not all countries used the same pro-
cedures on data collection and data monitoring, which is likely to have
contributed to the heterogeneity of the data. In particular, the Greek
children were all selected as having an identified mutation so overall
this group are likely to have a more “severe” FH phenotype than those
from other countries. We also did not collect data as to whether the
child was an index case or had been identified from cascade testing, and
this would be useful information to collect in the future. Finally, be-
cause of funding constraints we were not able to make a comprehensive
survey of the number of identified FH children in any of the countries
and only a single physician in each country was requested to submit the
data that they had. We therefore are unable to estimate what proportion
of the predicted number of FH children have been identified in each
country, but, as with adults with FH [1] it is likely to be extremely low.
4.2. Conclusions
Overall, the majority of children with FH in these eight countries are
being appropriately managed with regard to age of initiation and dose
of statin used. However, there are a sizable proportion, which differs
between countries, of children aged over 10 years old who have LDL-C
above the EAS guideline recommendation of 3.5 mmol/l, who are not
being treated with statin or other lipid lowering medication. Since ul-
trasound studies have demonstrated significant carotid intima-media
thickening in non-treated FH children of this age compared to their
non-FH siblings [34–36], and clinical trials have shown that statin
treatment can reverse this [19,37,38], considering initiation of statin
therapy by the age of 8–10 years is a recommendation in most recent
guidelines [9–14]. While, for ethical and practical reasons, there are no
long term randomised-placebo controlled trials to examine the benefit
of statin initiation at this age and LDL-C level, observational studies
over at least 20 years support the reduction of CVD risk associated with
this approach [17]. While the proportion of children over the age of 10
years being treated with ezetimibe varies widely across Europe, the vast
majority of those taking this medication do achieve the 3.5 mmol/l
LDL-C target. While further long-term data from registries such as this
would be valuable to confirm the safety and benefit of early statin
therapy, working with paediatricians to emphasise the high but
avoidable risk of future premature CHD risk in untreated young people
with FH, and to develop tools to help clinicians appropriately assess this
risk, is therefore a priority.
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